Rabbit Recombinant Monoclonal FADS1 antibody - conjugated to Alexa Fluor® 594.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
Isoform 1. Acts as a front-end fatty acyl-coenzyme A (CoA) desaturase that introduces a cis double bond at carbon 5 located between a preexisting double bond and the carboxyl end of the fatty acyl chain. Involved in biosynthesis of highly unsaturated fatty acids (HUFA) from the essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3) precursors. Specifically, desaturates dihomo-gamma-linoleoate (DGLA) (20:3n-6) and eicosatetraenoate (ETA) (20:4n-3) to generate arachidonate (AA) (20:4n-6) and eicosapentaenoate (EPA) (20:5n-3), respectively (PubMed:10601301, PubMed:10769175). As a rate limiting enzyme for DGLA (20:3n-6) and AA (20:4n-6)-derived eicosanoid biosynthesis, controls the metabolism of inflammatory lipids like prostaglandin E2, critical for efficient acute inflammatory response and maintenance of epithelium homeostasis. Contributes to membrane phospholipid biosynthesis by providing AA (20:4n-6) as a major acyl chain esterified into phospholipids. In particular, regulates phosphatidylinositol-4,5-bisphosphate levels, modulating inflammatory cytokine production in T-cells (By similarity). Also desaturates (11E)-octadecenoate (trans-vaccenoate)(18:1n-9), a metabolite in the biohydrogenation pathway of LA (18:2n-6) (By similarity). Isoform 2. Does not exhibit any catalytic activity toward 20:3n-6, but it may enhance FADS2 activity.
FADSD5, FADS1, Acyl-CoA (8-3)-desaturase, Delta(5) fatty acid desaturase, Fatty acid desaturase 1, D5D, Delta(5) desaturase, Delta-5 desaturase
Rabbit Recombinant Monoclonal FADS1 antibody - conjugated to Alexa Fluor® 594.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
FADS1 also known as fatty acid desaturase 1 is an enzyme that introduces double bonds into fatty acid chains. This process is critical in polyunsaturated fatty acid biosynthesis. FADS1 has a molecular mass of approximately 52 kDa. The enzyme is expressed in a variety of tissues with significant presence in the liver where it plays an important role in lipid metabolism. The expression levels of FADS1 can vary based on dietary intake and the body's metabolic needs.
FADS1 catalyzes the desaturation of specific fatty acids by converting them into more unsaturated forms. It acts within the endoplasmic reticulum of cells and can function as part of a larger enzyme complex. The activity of FADS1 influences the levels of essential fatty acids like arachidonic acid and eicosapentaenoic acid which affect cellular membrane structure and signaling. This enzyme's action plays a significant role in creating lipid mediators that are important for anti-inflammatory processes and cellular communication.
The activity of FADS1 is integral to the omega-3 and omega-6 fatty acid metabolic pathways. These pathways have implications for cellular homeostasis and are related to energy balance and inflammatory responses. Enzymes such as FADS2 are closely related through these pathways operating in tandem to progressively desaturate and elongate fatty acids. The balance between FADS1 and FADS2 activities influences the product profiles of these pathways thereby affecting overall fatty acid composition in the body.
FADS1 has links to metabolic disorders including cardiovascular disease and dyslipidemia. Aberrations in FADS1 activity can lead to imbalanced fatty acid levels which may contribute to these conditions. There are studies suggesting its connection to inflammatory diseases through altered eicosanoid production impacting proteins like cyclooxygenase. Understanding the variations in FADS1 function and expression could aid in developing therapeutic strategies targeting metabolic health and inflammatory conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com